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Before going into a detailed discussion,
three points should be mentioned: First, the
argumentation of the Letter to the Editor is
highly biased, trying to focus the attention
on a comparison with capecitabine. Our Re-
view [Oncology 2003;64:191–206; refer-
ences relevant to our Review and the Letter
to the Editor by Drs. Reichardt and Miles
are cited in alphabetical order in the refer-
ence list of this Reply] was designed to evalu-
ate the efficacy of gemcitabine and not to
provide an analysis of the whole spectrum of
treatments possible. While capecitabine is
undoubtedly effective in breast cancer, it is
certainly not the only drug gemcitabine
could be compared with. Moreover, a face-
to-face comparison of gemcitabine and cape-
citabine has never been performed. A vali-
dating comparison of both agents should,
therefore, be avoided at the present time.
Second, as indicated in the text, our Review
is based solely on results from phase II trials.
While almost everybody would agree that
such data being subject to various selection
biases tend to give a more optimistic picture
of drug efficacy, we also need to concede that
the contrast may happen and a negative
result may be reported. Phase II data should,
therefore, be compared with great caution.
However, in view of a large and consistent
body of evidence, we maintain our conclu-
sion that gemcitabine is an effective and
well-tolerated agent in the treatment of met-
astatic breast cancer. Third, drug develop-
ment, in our view, is meant to enlarge the
choice of available drugs for the patient and
not to open a scenario of competing agents.
The commentary by Drs. Reichardt and
Miles makes several broad statements with
little data to support their claims. As re-
ported in the Review, gemcitabine has
shown activity in nine well-designed single-
agent trials conducted in patients with meta-
static breast cancer (table 1 in the Review).
These trials have included patients with
varying types of prior therapy, with re-
sponses seen in all different settings. The
trials selected for our Review include ade-
quate patient numbers as well as have passed
a peer review venue. We appreciate the thor-
oughness in mentioning two additional stud-
ies not included in our Review and will com-
ment further on these studies.
The US study mentioned in the report by
Carmichael and Walling [1996; ref. 3 in the
Letter to the Editor] included only 15 evalu-
able patients, none of whom achieved a
remission. The European trial also described
in this publication observed a response rate
of 25% (95% CI 12.7–41.2%) among 40 eva-
luable patients. The authors of this paper
conclude that ‘the reasons for this difference
are far from clear, although patients were
more heavily pretreated in the US study and
these patients received a lower dose of che-
motherapy’. The mean dose of gemcitabine
in the US study was 565 mg/m2, while it was
727 mg/m2 in the European study. By to-
day’s standards, the US dose is certainly con-
sidered inadequate.
The higher toxicity noted in the US study
may be explained by a more intensive pre-
treatment. The European trial described by
Carmichael and Walling [1996; ref. 3 in the
Letter to the Editor] allowed only one pre-
vious chemotherapy. In view of the more
robust data based on 40 evaluable patients,
the authors concluded that ‘gemcitabine was
extremely well tolerated in both studies,
even in heavily pretreated patients’ and went
on stating that ‘in view of its modest toxicity
profile ... and its relative lack of myelotoxici-
ty gemcitabine would be an ideal candidate
for combination chemotherapy’. Due to the
low patient number and the rather incom-
plete data available, we confirm the decision
not to include the US study into the Review.
Considering the inconsistencies between the
data reported by Carmichael and Walling
[1996; ref. 3 in the Letter to the Editor] and
those quoted by Reichardt and Miles in their
commentary, the question on their database
needs to be raised.
With regard to the trial performed by
Smorenburg et al. [2001; ref. 21 in the Re-
view], this study examined 23 heavily pre-
treated patients with metastatic breast can-
cer who had failed on both an anthracycline-
and taxane-containing regimen and found
no responders. Visceral disease was ob-
served in 74%, and 57% of the patients had
three or more organ systems involved. De-
spite all but 3 patients received gemcitabine
as third-line (or greater) treatment for meta-
static disease, 26% of these patients reached
stable disease with a median duration of 4.0
months. These data should be interpreted
together with two other studies performed in
anthracyline- and taxane-pretreated patients
showing response rates of 16–23% [Brodo-
wicz et al., 2000; Valerio et al., 2001 – refs.
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16 and 17 in the Review]. From these trials,
it is evident that gemcitabine is active in
anthracycline- and taxane-pretreated breast
cancer patients.
The randomized trial comparing gemci-
tabine and epirubicin in elderly patients pre-
sented at the European Breast Cancer Con-
ference in April 2002 [Feher et al., 2002; ref.
11 in the Letter to the Editor]was not in-
cluded into the Review, since the manu-
script had been finalized long before publica-
tion of these data. Adequate room for discus-
sion will be found at due time together with
other randomized trials now available for
gemcitabine-based regimens.
The commentary by Reichardt and Miles
recommends that ‘until gemcitabine demon-
strates sufficient activity to merit regulatory
approval as treatment for metastatic breast
cancer...’, oncologists should continue to
study the available data of gemcitabine. The
author apparently failed to recognize that
O’Shaughnessy et al. [2003; ref. added in this
Reply] presented the registration trial of
gemcitabine combined with paclitaxel as
compared with paclitaxel as first-line treat-
ment in patients with metastatic breast can-
cer at the ASCO Meeting 2003. This trial
showed statistically significant improve-
ments in overall response rate and time to
progressive disease with a manageable toxic-
ity profile for the gemcitabine/paclitaxel
combination. The results of this trial have
been a key component in the global registra-
tion of gemcitabine for the treatment of met-
astatic breast cancer. While gemcitabine had
already been registered for breast cancer
treatment in several European countries, re-
gistration has now been achieved also in
Germany.
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